Company intelligence / Profile preview

Calosyn Pharma

Shreveport, Louisiana, United Statescalosyn.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Calosyn Pharma’s lead candidate CAL-05CR, a sustained-release injectable formulation of verapamil targeting the Cav1.2 calcium channel, has demonstrated significant pain reduction and cartilage preservation in moderate to severe osteoarthritis patients in human studies. The company leverages over 20 years of research and has completed three IRB studies showing positive clinical results with minimal side effects compared to standard treatments. The product is currently advancing through Phase 2 clinical trials.[1][3][8]

Therapeutic areas: Rheumatology
Modalities: Small molecules (sustained-release injectable verapamil)
Industry: Biotech

Drug pipeline

1 asset

CAL-05CR

Unknown

Partnerships

Louisiana Fund I/Ventures MD Anderson Focus Fund (investors/board representation)[5]

Beyond the preview

Go deeper on Calosyn Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calosyn Pharma.

Explore the full profile